Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Vaccines01:30

Cancer Vaccines

352
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
352
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
Gene Therapy00:59

Gene Therapy

25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

889
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
889

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The changing epidemiology of <i>Candida</i> species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios.

Expert review of anti-infective therapy·2025
Same author

Correction: Tegileridine: First Approval.

Drugs·2024
Same author

Ivonescimab: First Approval.

Drugs·2024
Same author

Tarlatamab: First Approval.

Drugs·2024
Same author

Tovorafenib: First Approval.

Drugs·2024
Same author

Aprocitentan: First Approval.

Drugs·2024
Same journal

Advances in Gene and Cellular Therapy in Friedreich Ataxia.

Molecular diagnosis & therapy·2026
Same journal

Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer.

Molecular diagnosis & therapy·2026
Same journal

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same journal

Genetics of Cerebrotendinous Xanthomatosis.

Molecular diagnosis & therapy·2026
Same journal

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026
Same journal

LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.

Molecular diagnosis & therapy·2026
查看所有相关文章

相关实验视频

Updated: Jun 23, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

泽沃卡巴泰基因自杀剂:首次获得批准

Sohita Dhillon1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular diagnosis & therapy
|June 18, 2024
PubMed
概括
此摘要是机器生成的。

针对BCMA的CAR T细胞疗法Zevorcabtagene autoleucel在中国已被批准用于复发性/耐药性多发性髓瘤. 这标志着治疗晚期多发性骨髓瘤患者的重要里程碑.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

486

相关实验视频

Last Updated: Jun 23, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

486

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

背景情况:

  • 多发性骨髓瘤是一种血液性恶性瘤,其特征是不受控制的血细胞增殖.
  • 复发性或耐药性多发性骨髓瘤带来了严重的治疗挑战,治疗选择有限.
  • B细胞成熟抗原 (BCMA) 是多发性骨髓瘤治疗中验证的标.

研究的目的:

  • 要总结zevorcabtagene autoleucel. 的发展和里程碑.
  • 为了突出第一个监管批准zevorcabtagene autoleucel用于多发性骨髓瘤.
  • 提供治疗作用机制和临床发展的概述.

主要方法:

  • 泽沃卡巴基因自细胞是一种自的CAR T细胞疗法,旨在向BCMA.
  • 该疗法结合了完全人类的BCMA特异性scFv (25C2),CD8α,4-1BB和CD3-ζ域.
  • 开发涉及临床前研究和临床试验,以评估安全性和有效性.

主要成果:

  • 泽沃卡巴泰基因自身细胞对表达BCMA的瘤细胞具有选择性毒性.
  • 在2024年2月,它在中国获得了首次批准,用于复发性或耐火性多发性骨髓瘤.
  • 该批准是针对在至少三种先前疗法后进展的患者.

结论:

  • 泽沃卡巴泰基因自细胞为复发性或耐火性多发性髓瘤患者提供了一种新的治疗选择.
  • 第一次批准意味着CAR T细胞治疗血液恶性瘤的重大进展.
  • 加拿大和美国正在进行的临床研究将进一步评估其在不同患者群体中的潜力.